Abstract Over the last few years several studies led to a significant change in the field of ovarian cancer and it is currently believed that the fallopian tube and not the ovary surface epithelium (OSE) is the main origin of high-grade serous ovarian cancer (HG-SOC). Nevertheless, due to the lack of unique markers and adequate model systems the relative contribution of each tissue is not yet clear and the notion that OSE has a role in HG-SOC development was not cast aside altogether. In this work we have established novel organoid systems derived from both mouse OSE and oviduct (Ovi, the equivalent of human fallopian tube). These systems recapitulate their tissue of origin and demonstrate differences in medium requirements as well as gene expression. To establish comparable tumor progression models for both OSE and Ovi we used CRISPR-Cas9 technique and targeted commonly mutated genes in ovarian cancer (Trp53, Brca1, Nf1 and Pten). Thus, we were able to establish clones with different combinations of mutations. Histological, metaphase spread and gene expression analysis of the mutated organoid clones from both OSE and Ovi demonstrated different degrees of deviation from their wild type counterpart. This deviation became more evident as the amount of introduced mutations increased. Preliminary transplantation experiments showed that only triple mutants gave rise to tumors (Trp53, Brca1 and Pten or Trp53, Brca1 and Nf1). Moreover, Ovi mutant clones were more prone to grow into tumors in comparison to OSE as no tumors have been detected in mice transplanted with the OSE equivalent clones so far. Taken together, in this study we present the first comparable Ovi/OSE research platform that enables addressing questions related to origin and early stages of HG-SOC development. Citation Format: Kadi Lõhmussaar, Oded Kopper, Hans C. Clevers. BUILDING AN ORGANOID-BASED MODEL FOR OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr GMM-039.
Britton Trabert, Shelley S. Tworoger, Katie M. O’Brien, Mary K. Townsend, Renée T. Fortner, Edwin S. Iversen, Patricia Hartge, Emily White, Pilar Amiano, Alan A. Arslan, Leslie Bernstein, Louise A. Brinton, Julie E. Buring, Laure Dossus, Gary E. Fraser, Mia M. Gaudet, Graham G. Giles, Inger Torhild Gram, Holly R. Harris, Judith Hoffman Bolton, Annika Idahl, Michael E. Jones, Rudolf Kaaks, Victoria A. Kirsh, Synnøve F. Knutsen, Marina Kvaskoff, James V. Lacey, I‐Min Lee, Roger L. Milne, N. Charlotte Onland‐Moret, Kim Overvad, Alpa V. Patel, Ulrike Peters, Jenny N. Poynter, Elio Riboli, Kim Robien, Thomas E. Rohan, Dale P. Sandler, Catherine Schairer, Leo J. Schouten, Veronica Wendy Setiawan, Anthony J. Swerdlow, Ruth C. Travis, Antonia Trichopoulou, Piet A. van den Brandt, Kala Visvanathan, Lynne R. Wilkens, Alicja Wolk, Anne Zeleniuch‐Jacquotte, Nicolas Wentzensen
Johanna F. Dekkers, James R. Whittle, François Vaillant, Huei-Rong Chen, Caleb A. Dawson, Kevin Liu, Maarten H. Geurts, Marco J. Herold, Hans Clevers, Geoffrey J. Lindeman, Jane E. Visvader
Britton Trabert, Shelley S. Tworoger, Katie M. O’Brien, Mary K. Townsend, Renée T. Fortner, Edwin S. Iversen, Patricia Hartge, Emily White, Pilar Amiano, Alan A. Arslan, Leslie Bernstein, Louise A. Brinton, Julie E. Buring, Laure Dossus, Gary E. Fraser, Mia M. Gaudet, Graham G. Giles, Inger Torhild Gram, Holly R. Harris, Judith Hoffman Bolton, Annika Idahl, Michael E. Jones,
Elio Riboli, Kim Robien, Thomas E. Rohan, Dale P. Sandler, Catherine Schairer, Leo J. Schouten, Veronica Wendy Setiawan, Anthony J. Swerdlow, Ruth C. Travis, Antonia Trichopoulou, Piet A. van den Brandt, Kala Visvanathan, Lynne R. Wilkens, Alicja Wolk, Anne Zeleniuch‐Jacquotte, Nicolas Wentzensen, Britton Trabert, Shelley S. Tworoger, Katie M. O’Brien, Mary K. Townsend, Renée T. Fortner,
Discussion(0)
No comments yet. Be the first to comment.